Compare Stocks: VKTX, MOR, AMPH, and INDV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$27.39 +4.8%	$22.03	$16.65 ▼ $29.52	$1.17B	0.92	521,253 shs	747,940 shs
INDV Indivior	$36.88 +3.0%	$37.08	$22.56 ▼ $42.81	$4.35B	0.82	2.18 million shs	1.16 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
VKTX Viking Therapeutics	$33.03 -7.1%	$33.83	$25.04 ▼ $43.15	$3.85B	0.69	3.02 million shs	8.55 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+10.63%	+18.72%	+26.17%	-2.68%
INDV Indivior	0.00%	+2.69%	+2.72%	-13.18%	+49.75%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
VKTX Viking Therapeutics	0.00%	+22.66%	+10.57%	-10.07%	+39.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$27.39 +4.8%	$22.03	$16.65 ▼ $29.52	$1.17B	0.92	521,253 shs	747,940 shs
INDV Indivior	$36.88 +3.0%	$37.08	$22.56 ▼ $42.81	$4.35B	0.82	2.18 million shs	1.16 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
VKTX Viking Therapeutics	$33.03 -7.1%	$33.83	$25.04 ▼ $43.15	$3.85B	0.69	3.02 million shs	8.55 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+10.63%	+18.72%	+26.17%	-2.68%
INDV Indivior	0.00%	+2.69%	+2.72%	-13.18%	+49.75%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
VKTX Viking Therapeutics	0.00%	+22.66%	+10.57%	-10.07%	+39.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-17.85% Downside
INDV Indivior	2.71	Moderate Buy	$45.17	22.47% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
VKTX Viking Therapeutics	2.75	Moderate Buy	$99.67	201.75% Upside

Current Analyst Ratings Breakdown

Latest VKTX, MOR, AMPH, and INDV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/23/2026	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$83.00 ➝ $87.00
9/22/2026	VKTX Viking Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/22/2026	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/4/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/21/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	VKTX Viking Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$75.00 ➝ $65.00
8/7/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.62	$4.46 per share	6.14	$17.17 per share	1.60
INDV Indivior	$1.24B	3.51	$2.80 per share	13.17	($0.78) per share	-47.28
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	16.21	10.58	5.03	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
INDV Indivior	$210M	$2.79	13.22	9.63	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest VKTX, MOR, AMPH, and INDV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A
6/30/2026	Q2 2026	INDV Indivior	N/A	$5.75	N/A	$4.90	N/A	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest VKTX, MOR, AMPH, and INDV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/17/2026	INDV Indivior	special	$8.13		10/30/2026	10/30/2026	11/6/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
INDV Indivior	N/A	0.84	0.66
MOR MorphoSys	4.98	1.38	1.38
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
INDV Indivior	60.33%
MOR MorphoSys	18.38%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
INDV Indivior	0.74%
MOR MorphoSys	0.05%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
INDV Indivior	838	118.03 million	117.16 million	Not Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
VKTX Viking Therapeutics	65	116.65 million	110.47 million	Optionable

VKTX, MOR, AMPH, and INDV Headlines

Recent News About These Companies

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase ...

2 hours ago | markets.ft.com

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

2 hours ago | finance.yahoo.com

3 hours ago | prnewswire.com

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

September 28 at 12:16 PM | finance.yahoo.com

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

September 28 at 11:12 AM | prnewswire.com

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

September 28 at 10:31 AM | zacks.com

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution

September 27 at 12:43 PM | fool.com

3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing

September 27 at 4:55 AM | fool.com

Viking Therapeutics Stock Falls 15% After $483 Mln Equity And Convertible Notes Offering

September 26 at 2:49 PM | rttnews.com

Is Viking Therapeutics, Inc. (VKTX) the Healthcare Stocks Stock Everyone's About to Talk About?

September 26 at 2:49 PM | kalkinemedia.comK

MarketBeat Week in Review – 09/21 - 09/25 (VKTX)

...

September 26 at 7:00 AM | marketbeat.com

Viking Therapeutics, Inc. $VKTX Shares Newly Acquired by Bank of America Corp DE

September 26 at 3:06 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Stock Bumped Up to "Sell" by Wall Street Zen

September 26 at 1:24 AM | americanbankingnews.com

Viking Therapeutics (NASDAQ:VKTX) Stock Rating Raised to Sell at Wall Street Zen

September 26 at 1:23 AM | marketbeat.com

Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data?

September 25 at 7:23 PM | finance.yahoo.com

Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes

September 25 at 9:22 AM | legaldesire.comL

Viking Therapeutics (NASDAQ:VKTX) Sees Strong Trading Volume - Time to Buy?

September 25 at 6:24 AM | americanbankingnews.com

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

September 25 at 6:05 AM | fool.com

Best Mid Cap Stocks Worth Watching - September 22nd

September 25 at 5:34 AM | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Moderate Buy" from Analysts

September 25 at 2:28 AM | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock Has Average Target Price of $99.67

September 25 at 2:28 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VKTX, MOR, AMPH, and INDV Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$27.39 +1.26 (+4.82%)

Closing price 04:00 PM Eastern

Extended Trading

$28.00 +0.61 (+2.22%)

As of 07:30 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Indivior NASDAQ:INDV

$36.88 +1.06 (+2.96%)

Closing price 04:00 PM Eastern

Extended Trading

$36.30 -0.58 (-1.57%)

As of 07:30 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 09/25/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Viking Therapeutics NASDAQ:VKTX

$33.03 -2.53 (-7.11%)

Closing price 04:00 PM Eastern

Extended Trading

$33.12 +0.09 (+0.27%)

As of 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VKTX, MOR, AMPH, and INDV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VKTX, MOR, AMPH, and INDV Earnings

Compare Dividends

Latest VKTX, MOR, AMPH, and INDV Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VKTX, MOR, AMPH, and INDV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VKTX, MOR, AMPH, and INDV Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Indivior NASDAQ:INDV

MorphoSys NASDAQ:MOR

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools